Influx Healthtech Ltd, a Maharashtra-based company operating in the health and wellness sector, launched its IPO on June 18, 2025, aiming to raise ₹55.63 crore. The SME IPO is open for subscription until June 20. With a grey market premium of ₹40 per share, market participants expect a potential listing price of ₹136. The proceeds will fund new manufacturing units and corporate expenses, while shares are expected to list on the NSE SME platform on June 25.
Influx Healthtech Ltd, a Thane-based healthcare and wellness company, opened its initial public offering (IPO) for public subscription on June 18, 2025. The SME IPO aims to raise ₹55.63 crore and will remain open until June 20. The price band has been fixed between ₹91 and ₹96 per equity share.
Operating in the nutraceuticals, cosmetics, ayurvedic, and veterinary health space, Influx Healthtech functions as a contract development and manufacturing organization (CDMO). It manufactures tablets, gummies, jellies, skincare solutions, and herbal products from its existing facilities in Maharashtra.
Grey Market Premium Signals Optimism
In the grey market, shares of Influx Healthtech traded at a premium of ₹40 as of June 18. This reflects a projected listing price of ₹136 per share—indicating a 41.67% upside from the upper end of the IPO price band. While GMP is based on unofficial market sentiment, it is often seen as a proxy for listing expectations.
IPO Structure and Investment Details
The IPO includes a fresh issue of 46.94 lakh equity shares worth ₹45.07 crore and an offer for sale (OFS) of 11 lakh shares worth ₹10.56 crore. Retail investors were required to apply for a minimum of 1,200 shares, translating to an investment of about ₹1.15 lakh.
The proceeds will primarily fund the establishment of two new manufacturing units—focused on nutraceutical and veterinary health segments—along with machinery purchases and general corporate expenses. ₹34.19 crore has been earmarked specifically for manufacturing facility expansion.
Key Dates and Allotment Timeline
- Allotment Finalization: June 23
- Demat Credit/Refunds: June 24
- Listing on NSE SME: June 25
Expert Viewpoint
According to IPO analyst Dilip Davda of Chittorgarh.com, Influx Healthtech has shown stable revenue growth, reporting ₹104.99 crore in revenue and ₹13.37 crore in net profit in FY25. However, he expressed concerns over the sudden profit surge and advised a cautious, medium-term investment outlook, rating the IPO as ‘may apply.’
IPO Management
The IPO is being managed by Rarever Financial Advisors Pvt. Ltd., while Maashitla Securities Pvt. Ltd. serves as the registrar. R.K. Stock Holding Pvt. Ltd. has been appointed as the market maker for the issue.
As India’s health and wellness market continues to expand rapidly, Influx Healthtech’s IPO offers a new avenue for investors betting on the nutraceutical and wellness wave across urban and semi-urban areas.
